Transcatheter Heart Valves Market: Rising Prevalence of Valvular Heart Diseases to Drive Market Growth to US$ 7,962.56 Million by 2033

As per the latest market research by Business Market Insights (BMI), the research report "Transcatheter Heart Valves Market Size and Forecast (2025–2033)" forecasts how the market is set to surge 127.93% by 2033. The global transcatheter heart valves market is driven by the rising prevalence of valvular heart diseases and the rapid growth of the elderly population. Increasing preference for minimally invasive, catheter-based procedures over open-heart surgery is accelerating adoption. Expanding clinical indications into intermediate- and low-risk patients, along with continuous advancements in valve design and delivery systems, are further supporting sustained market growth.

The report forecasts the market to expand from US$ 3,493.36 million in 2024 to US$ 7,962.56 million by 2033, registering a robust CAGR of 9.59% over the 2025–2033 period.

The global transcatheter heart valves market is an integral part of the structural heart disease landscape, offering minimally invasive alternatives to surgical valve replacement. These therapies are primarily used for treating aortic, mitral, and tricuspid valve disorders, particularly in patients at high or intermediate surgical risk. Market growth is driven by increasing prevalence of valvular heart diseases, aging populations, and strong clinical evidence supporting transcatheter interventions. Technological advancements in valve materials, delivery systems, and imaging guidance have improved procedural safety, durability, and outcomes. Additionally, expanding indications, growing adoption in emerging markets, and rising investments in cardiac care infrastructure are strengthening the global uptake of transcatheter heart valve technologies.

Overview of report findings

Market Growth

The transcatheter heart valves market is projected to grow from US$ 3,493.36 million in 2024 to US$ 7,962.56 million by 2033, registering a compound annual growth rate (CAGR) of 9.59% between 2025 and 2033.

The global transcatheter heart valves market is driven by the rising prevalence of valvular heart diseases and the rapid growth of the elderly population. Increasing preference for minimally invasive, catheter-based procedures over open-heart surgery is accelerating adoption. Expanding clinical indications into intermediate- and low-risk patients, along with continuous advancements in valve design and delivery systems, are further supporting sustained market growth.

Rising Prevalence of Valvular Heart Diseases

The rising prevalence of valvular heart diseases is a fundamental driver of the global transcatheter heart valves market. Degenerative valve conditions, including aortic stenosis and mitral regurgitation, are increasing steadily due to aging populations, longer life expectancy, and lifestyle-related risk factors such as hypertension, diabetes, obesity, and smoking. Improved availability of echocardiography, cardiac computed tomography, and advanced imaging techniques has significantly enhanced diagnosis rates, enabling earlier detection of valve dysfunction across diverse patient groups. As disease burden rises, healthcare systems face growing pressure to deliver effective, durable, and less invasive treatment solutions. Transcatheter heart valve therapies address this demand by providing an alternative to surgical valve replacement, particularly for patients at high or intermediate surgical risk. Expanding clinical evidence, favorable guideline updates, and increasing physician confidence are accelerating adoption of transcatheter aortic valve replacement procedures. In parallel, growing research activity and early commercialization of transcatheter mitral and tricuspid interventions are broadening the addressable patient population. This sustained increase in diagnosed valvular heart disease cases directly supports long-term demand for transcatheter valve technologies worldwide. Rising procedure volumes and expanding hospital infrastructure investments further reinforce market momentum across developed and emerging healthcare systems globally over the forecast period for structural heart care.

Growing Geriatric Population

The growing geriatric population is a critical driver of the global transcatheter heart valves market. Aging is strongly associated with degenerative changes in cardiac valve structures, including calcification, reduced elasticity, and progressive functional deterioration. As a result, elderly individuals experience higher incidence of aortic stenosis, mitral regurgitation, and tricuspid valve disorders requiring clinical intervention. Older patients frequently present with multiple comorbidities such as renal dysfunction, pulmonary disease, diabetes, and frailty, which increase the risks associated with conventional open-heart surgery. Transcatheter heart valve procedures offer a minimally invasive alternative with lower procedural risk, reduced anesthesia burden, faster recovery, and shorter hospital stays. These benefits make catheter-based valve therapies particularly suitable for elderly and high-risk patients. Rapid growth of the aging population in North America, Europe, Japan, and parts of Asia Pacific is expanding the eligible treatment pool. This demographic shift is driving higher procedure volumes, encouraging hospitals to expand structural heart programs, and supporting sustained market growth globally. Longer life expectancy, improved post-procedural outcomes, and growing physician confidence continue to accelerate adoption of transcatheter valve therapies within aging populations worldwide across public and private healthcare systems focused on reducing surgical risk and hospitalization burden in elderly cardiac patients globally today populations.

Geographic Insights

North America dominates the transcatheter heart valves market due to high prevalence of valvular heart diseases, advanced healthcare infrastructure, and early adoption of innovative cardiac technologies. Strong reimbursement frameworks, high procedural volumes, and widespread availability of experienced structural heart centers support market leadership. Presence of leading manufacturers, continuous clinical trials, and rapid regulatory approvals further accelerate adoption of transcatheter aortic, mitral, and tricuspid valve therapies across major healthcare systems regionwide.

Europe is the second-largest transcatheter heart valves market, supported by aging populations, rising burden of valvular heart diseases, and well-established public healthcare systems. Countries such as Germany, France, and the United Kingdom have strong structural heart programs and high procedure adoption. Favorable clinical guidelines, expanding reimbursement coverage, and ongoing technology upgrades continue to sustain steady market growth across the region for transcatheter aortic, mitral, and tricuspid valve interventions nationwide adoption.

Asia Pacific is the fastest-growing region in the transcatheter heart valves market due to large patient populations, rapidly increasing valvular disease burden, and expanding access to cardiac care. Rising healthcare investments, improving hospital infrastructure, and growing physician expertise are driving adoption. China, India, and Southeast Asia are witnessing accelerated uptake supported by government initiatives and increasing awareness of minimally invasive structural heart interventions across emerging healthcare markets in region overall.

Market Segmentation

• By valve type, the transcatheter heart valves market is segmented into aortic valve, mitral valve, tricuspid valve, and pulmonary valve. The aortic valve segment dominated the market in 2024. Owing to the high prevalence of aortic stenosis, growing preference for minimally invasive transcatheter aortic valve replacement (TAVR), and technological advancements ensuring improved patient outcomes and procedural safety
• Based on application, the transcatheter heart valves market is segmented into aortic valve diseases, mitral valve diseases, tricuspid valve diseases, and pulmonary valve diseases. The aortic valve disease segment dominated the market in 2024. Rising cases of calcific aortic stenosis and aging populations increased demand for transcatheter interventions, making it the most treated condition requiring advanced valve replacement solutions.
• In terms of end user, the transcatheter heart valve market is segmented into hospitals, ambulatory surgical centers, and cardiac catheterization labs. The hospitals segment dominated the market in 2024. Hospitals serve as primary centers for complex cardiovascular procedures, offering advanced infrastructure, skilled cardiologists, and comprehensive patient care, making them the leading setting for transcatheter heart valve adoption.

Competitive Strategy & Development

Key Players: The transcatheter heart valves market is populated by several key players, each contributing to its growth and innovation. Some prominent players are:

1. Medtronic
2. Boston Scientific Corporation
3. Abbott
4. Edwards Lifesciences Corporation
5. Meril Life Sciences
6. MicroPort Scientific Corporation
7. Venus Medtech (Hangzhou) Inc.
8. SMT Medical
9. HighLife Medical
10. Products & Features GmbH

Trending Topics: Interventional Coronary Catheters, Coronary Stents, Peripheral Stents, PTCA Balloons, Guidewires and Introducer Sheaths, Drug-Eluting Balloons, Bioresorbable Scaffolds, Imaging-Guided Catheters, Hydrophilic Coated Catheters, Steerable Catheters, Radial Access Catheters, Microcatheters

Global Headlines

• Abbott announced approval of Tendyne™ TMVR system – In May 2025, Abbott announced the U.S. Food and Drug Administration (FDA) has approved the company's Tendyne™ transcatheter mitral valve replacement (TMVR) system to treat people with mitral valve disease.
• Edwards announced approval of SAPIEN 3 – In May 2025, Edwards Lifesciences announced that the U.S. Food and Drug Administration (FDA) has approved its transcatheter aortic valve replacement (TAVR) therapy, the SAPIEN 3 platform, for severe aortic stenosis (AS) patients without symptoms, marking the first FDA approval for TAVR in asymptomatic patients.
• Edwards Lifesciences announced approval of SAPIEN M3 mitral valve – In April 2025, Edwards Lifesciences Corporation announced the company’s SAPIEN M3 mitral valve replacement system received CE Mark for the transcatheter treatment of patients with symptomatic mitral regurgitation.

Conclusion

The global transcatheter heart valves market is poised for sustained growth, driven by rising valvular heart disease prevalence, aging populations, and strong clinical acceptance of minimally invasive therapies. Continuous technological advancements are improving valve durability, procedural safety, and patient outcomes, expanding adoption beyond high-risk patients. North America and Europe provide stable demand supported by advanced infrastructure and reimbursement, while Asia Pacific offers significant growth opportunities due to expanding access and investment. Ongoing expansion into mitral and tricuspid applications, favorable clinical guidelines, and increasing structural heart program development are expected to strengthen market momentum, positioning transcatheter heart valves as a cornerstone of future valvular disease management globally across public and private healthcare systems worldwide and rapidly expanding physician expertise worldwide.